Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials

• Published in: Annals of internal medicine Vol. 117; no. 9; p. 739
• Main Authors: Henry, D H, Beall, G N, Benson, C A, Carey, J, Cone, L A, Eron, L J, Fiala, M, Fischl, M A, Gabin, S J, Gottlieb, M S
• Format: Journal Article
• Language: English
• Published: United States 01.11.1992
• Subjects: Acquired Immunodeficiency Syndrome - complications; Acquired Immunodeficiency Syndrome - drug therapy; Adult; Anemia - blood; Anemia - drug therapy; Anemia - etiology; Blood Transfusion; Dose-Response Relationship, Drug; Double-Blind Method; Erythropoietin - adverse effects; Erythropoietin - blood; Erythropoietin - therapeutic use; Female; Hematocrit; Humans; Male; Middle Aged; Quality of Life; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Statistics as Topic; Zidovudine - adverse effects; Zidovudine - therapeutic use

To assess the effect of recombinant human erythropoietin (r-HuEPO) on anemia in patients with the acquired immunodeficiency syndrome (AIDS) who are receiving zidovudine therapy. Combined analysis of four 12-week, randomized, double-blind, controlled clinical trials. Multiple centers in the United St...